About
Titles
Hospital Resident
Education & Training
- MD
- SUNY Downstate Medical Center College of Medicine (2021)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Syed Rahman's published research.
Michael S. Leapman, MD, MHS
Preston C. Sprenkle, MD
Ankur Choksi, MD
Cary Gross, MD
David G. Hesse, MD
Michael Hurwitz, MD, PhD
Publications
2024
Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis
Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024 PMID: 38959160, DOI: 10.1089/sur.2024.107.Peer-Reviewed Original ResearchAltmetricConceptsSurgical site infectionBody mass indexRadical cystectomyCenters for Disease Control and PreventionIndependent risk factorLength of stayRisk factorsAntibiotic agentsSite infectionCenters for Disease Control and Prevention classificationRisk factors of surgical site infectionFactors associated with surgical site infectionFactors of surgical site infectionPredictive of surgical site infectionDeep incision surgical site infectionSurgical site infection predictorsOdds ratioTreatment of surgical site infectionsDeep surgical site infectionPeri-operative characteristicsPeri-operative morbidityCharlson Comorbidity IndexLogistic regression analysisSuperficial incisionalDisease Control and PreventionHF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE
Lokeshwar S, Shaheen D, Choksi A, Patel M, Rahman S, Martin T, Hesse D, Leapman M. HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE. Journal Of Urology 2024, 211: e282. DOI: 10.1097/01.ju.0001008828.35887.de.10.Peer-Reviewed Original ResearchMP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.Peer-Reviewed Original ResearchMP75-10 NOCTURIA ACROSS THE HEART FAILURE CONTINUUM: RESULTS FROM AN OUTPATIENT UROLOGY POPULATION
Yim S, Fang A, Ksido L, Morris M, Glover B, Rahman S, Weiss J, Tologonova G, Everaert K, DeBacker T, Roberts M, Salciccioli L, Lazar J, Monaghan T. MP75-10 NOCTURIA ACROSS THE HEART FAILURE CONTINUUM: RESULTS FROM AN OUTPATIENT UROLOGY POPULATION. Journal Of Urology 2024, 211: e1235. DOI: 10.1097/01.ju.0001008676.21744.5f.10.Peer-Reviewed Original ResearchArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantagePrevalence of Sleep CALM nocturia factors in a male veteran population
Monaghan T, Fang A, Ksido L, Hachicho C, Muneeb M, Rahman S, Kheir G, Lazar J, Everaert K, Wein A, Weiss J. Prevalence of Sleep CALM nocturia factors in a male veteran population. Neurourology And Urodynamics 2024, 43: 1127-1133. PMID: 38511613, DOI: 10.1002/nau.25410.Peer-Reviewed Original ResearchConceptsAssociated with advanced ageFrequency-volume chartUrinary tract dysfunctionSignificant diagnostic challengeMedical history dataMale veteran populationGenitourinary abnormalitiesNocturnal voidsUrinary tractDiagnostic challengeConsensus guidelinesHost of conditionsNocturiaRetrospective analysisUrology settingAdvanced agePatient populationMultifactorial conditionReal-world practiceSleep disordersNocturia patientsDifferential effects of ageEffects of ageMedication useSleepApplication of the Sleep C.A.L.M. Tool for Assessing Nocturia in a Large Nationally Representative Cohort
Boroda J, De Leon B, Khosla L, Chobufo M, Rahman S, Lazar J, Weiss J, Monaghan T. Application of the Sleep C.A.L.M. Tool for Assessing Nocturia in a Large Nationally Representative Cohort. International Neurourology Journal 2024, 28: s55-61. PMID: 38461857, PMCID: PMC10932577, DOI: 10.5213/inj.2346258.129.Peer-Reviewed Original ResearchCitationsConceptsOdds of nocturiaNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveySex subgroupsCommunity-dwelling adultsNutrition Examination SurveyAssociated with greater oddsAssociation of nocturiaAssociated with increased oddsNationally representative cohortDose-dependent fashionImpact patient qualityQuality of lifePhysical examination dataYears of ageAssess nocturiaNighttime voidsExamination SurveyNationally representative datasetNocturiaRepresentative cohortRetrospective analysisGreater oddsPertinent questionnairesPatients' quality
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchAltmetricConceptsMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosisProstate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsyManagement strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.Peer-Reviewed Original Research
Links & Media
News
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
- June 26, 2024
2024 Yale Urology Bernard Lytton Visiting Professor Day
- June 24, 2024
2024 Yale Urology Graduation Awards
- April 24, 2024
Yale Urology Research [Q1: January-March 2024]
Get In Touch
Contacts
Email